Literature DB >> 28499756

Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.

Qiong Shi1, Hongliang Liu2, Peng Han3, Chunying Li4, Yanru Wang2, Wenting Wu5, Dakai Zhu6, Christopher I Amos6, Shenying Fang7, Jeffrey E Lee7, Jiali Han8, Qingyi Wei9.   

Abstract

Cutaneous melanoma (CM) is the most lethal skin cancer. The Wnt pathway has an impact on development, invasion, and metastasis of CM, thus likely affecting CM prognosis. Using data from a published genome-wide association study from The University of Texas MD Anderson Cancer Center, we assessed the associations of 19,830 common single-nucleotide polymorphisms (SNPs) in 151 Wnt pathway autosomal genes with CM-specific survival and then validated significant SNPs in another genome-wide association study from Harvard University. In the single-locus analysis, 1,855 SNPs were significantly associated with CM-specific survival at P < 0.05, of which 547 SNPs were still considered noteworthy after the correction by the false-positive report probability. In the replication, two SNPs remained significantly associated with CM-specific survival after multiple comparison correction. By performing functional prediction and stepwise selection, we identified two independent SNPs (i.e., WNT2B rs1175649 G>T and BTRC rs61873997 G>A) that showed a predictive role in CM-specific survival, with an effect-allele-attributed hazards ratio (adjusted hazards ratio) of 1.99 (95% confidence interval = 1.41-2.81, P = 8.10 × 10-5) and 0.61 (0.46-0.80, 3.12×10-4), respectively. Collectively, these variants in the Wnt pathway genes may be biomarkers for outcomes of patients with CM, if validated by larger studies.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28499756      PMCID: PMC5548422          DOI: 10.1016/j.jid.2017.04.023

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  45 in total

1.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

2.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

4.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.

Authors:  D L Rimm; K Caca; G Hu; F B Harrison; E R Fearon
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

5.  Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.

Authors:  Véronique Delmas; Friedrich Beermann; Silvia Martinozzi; Suzanne Carreira; Julien Ackermann; Mayuko Kumasaka; Laurence Denat; Jane Goodall; Flavie Luciani; Amaya Viros; Nese Demirkan; Boris C Bastian; Colin R Goding; Lionel Larue
Journal:  Genes Dev       Date:  2007-11-15       Impact factor: 11.361

6.  Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome.

Authors:  Eric Kielhorn; Elayne Provost; Drew Olsen; Thomas G D'Aquila; Bradley L Smith; Robert L Camp; David L Rimm
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

Review 7.  The importance of Wnt signalling for neurodegeneration in Parkinson's disease.

Authors:  Daniel C Berwick; Kirsten Harvey
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

8.  Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.

Authors:  Maider Ibarrola-Villava; Rajiv Kumar; Eduardo Nagore; Meriem Benfodda; Mickael Guedj; Steven Gazal; Hui-Han Hu; Jian Guan; P Sivaramakishna Rachkonda; Vincent Descamps; Nicole Basset-Seguin; Armand Bensussan; Martine Bagot; Philippe Saiag; Dirk Schadendorf; Manuel Martin-Gonzalez; Matias Mayor; Bernard Grandchamp; Gloria Ribas; Nadem Soufir
Journal:  Int J Cancer       Date:  2014-10-24       Impact factor: 7.396

9.  Lineage-specific requirements of beta-catenin in neural crest development.

Authors:  Lisette Hari; Véronique Brault; Maurice Kléber; Hye-Youn Lee; Fabian Ille; Rainer Leimeroth; Christian Paratore; Ueli Suter; Rolf Kemler; Lukas Sommer
Journal:  J Cell Biol       Date:  2002-12-09       Impact factor: 10.539

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  2 in total

1.  Role of miR-214 in regulation of β-catenin and the malignant phenotype of melanoma.

Authors:  Kirthana Prabhakar; Carlos I Rodrίguez; Ashika S Jayanthy; Dareen M Mikheil; Aishwarya Iyer Bhasker; Ranjan J Perera; Vijayasaradhi Setaluri
Journal:  Mol Carcinog       Date:  2019-07-24       Impact factor: 4.784

2.  Single cell transcriptomic analysis of human pluripotent stem cell chondrogenesis.

Authors:  Chia-Lung Wu; Amanda Dicks; Nancy Steward; Ruhang Tang; Dakota B Katz; Yun-Rak Choi; Farshid Guilak
Journal:  Nat Commun       Date:  2021-01-13       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.